Clinigen Group Completes Acquisition of CSM

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, today announces that it has completed the acquisition of CSM Parent, Inc. ('CSM'), which was announced on 27 September 2018 (the "Acquisition").

Following Admission of the Placing Shares on 1 October 2018 (details of the Placing having been announced by the Company on 27 September 2018 to coincide with the announcement of the Acquisition), the Company now has in issue 131,949,754 ordinary shares of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury. This figure of 131,949,754 ordinary shares may be used by shareholders in Clinigen to determine if they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information, please contact:

Clinigen Group plc
Shaun Chilton, Group Chief Executive
Martin Abell, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Tel:+44 (0) 1283 495 010

Numis Securities Limited (Nominated Adviser, Joint Financial Adviser and Joint Corporate Broker to Clinigen)
Michael Meade
James Black
Freddie Barnfield
Tel: +44 (0)20 7260 1000

RBC Capital Markets (Joint Financial Adviser and Joint Corporate Broker to Clinigen)
Marcus Jackson
Thomas Stockman
Elliot Thomas
Tel: +44 (0)20 7653 4000

Instinctif Partners (FPR Adviser to Clinigen)
Adrian Duffield
Melanie Toyne Sewell
Alex Shaw
Tel: +44 (0)20 7457 2020

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

For more information, please visit www.clinigengroup.com